. . .

Eye Catching Stock News: Aethlon Medical (NASDAQ:AEMD)

On Friday Aethlon Medical (NASDAQ:AEMD) started its trading session with the price $4.45 and closed at price of $4.05 by scoring -10%. Day range of the stock was $3.9 – $4.45. AEMD stock traded with total volume of 31321 shares while the average trading capacity remained 38373 shares.  Earnings per share was $-5.13. AEMD has total market capitalization of $5382450.

On Nov. 1, 2019, Aethlon Medical (NASDAQ:AEMD) a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, released financial results for its second quarter ended September 30, 2019 and provided an update on recent developments.

Company Updates

Aethlon Medical is continuing the development of its proprietary Hemopurifier, which is a first in class therapeutic device designed for the single use depletion of cancer-promoting exosomes and circulating viruses.  The Hemopurifier has previously been designated a Breakthrough Device by the FDA for the treatment of glycosylated viruses, including Ebola and other hemorrhagic fever viruses, and in late 2018 was additionally designated as a Breakthrough Device …for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease…..Aethlon is currently preparing for the initiation of clinical trials in patients with advanced and metastatic cancers. The Company is initially focused on the treatment of solid tumors, including head and neck cancer, gastrointestinal cancers and other cancers.  In September 2019, the Company filed an Investigational Device Exemption (IDE) application to support an initial Early Feasibility Study (EFS) in patients with advanced and/or metastatic head and neck cancer, which was approved by FDA on October 4, 2019 subject to submission of a final patient informed consent form.  The Company is currently preparing to initiate a 10 to 12 subject EFS in patients with advanced and/or metastatic head and neck cancer.  The EFS will be performed at a major academic research center to investigate the combination of the Hemopurifier with standard of care pembrolizumab (Keytruda®).

Leave a Reply

Your email address will not be published. Required fields are marked *